Robert Karama, Burkina Faso
Ministry of Health Boucle du MouhounAuthor Of 1 Presentation
IMPACT OF PCV13 ON THE INCIDENCE OF HOSPITALIZATONS FOR ALL-CAUSE PNEUMONIA AMONG CHILDREN AGED LESS THAN 5 YEARS IN BURKINA FASO: AN INTERRUPTED TIME-SERIES ANALYSES (ID 371)
- Lassane Kabore, Burkina Faso
- Seydou Ouattara, Burkina Faso
- François Sawadogo, Burkina Faso
- Alain Gervaix, Switzerland
- Annick Galeto-Lacour, Switzerland
- Robert Karama, Burkina Faso
- Amado T. Traore, Burkina Faso
- Bertrand Meda, Burkina Faso
- Haoua Tall, Burkina Faso
- Alima T. Essoh, Burkina Faso
- Bradford D. Gessner, United States of America
- Jennifer C. Moïsi, France
Abstract
Background
Pneumococcal disease is a major public health concern globally and particularly in Burkina Faso where PCV13 was introduced nationwide into the routine immunization schedule in 2013. We sought to evaluate vaccine impact on all-cause pneumonia hospitalizations among children < 5 years.
Methods
We retrospectively collected hospitalization data over 10 years (January 1st 2009-December 31st 2018) in 4 rural district hospitals, using medical records to extract data on relevant variables. We used interrupted time series and segmented regression to estimate the effect and impact of PCV13 on the rates of pneumonia hospitalizations. Severe acute malnutrition and unintentional injury were used as control conditions.
Results
We found a vaccine effectiveness of 34% (95% CI : 16-49, p=0·001), 24% (95% CI : 2-41, p=0·032) and 50% (95% CI : 30-64, p<0·001) against all-cause pneumonia hospitalizations among children < 5 years, < 2 years, and 2-4 years, respectively. By October 2018, PCV13 had led to an absolute reduction in the pneumonia hospitalization rate of 348 cases per 100,000 among children < 5 years. No decline was observed for control conditions.
Conclusions
Our estimates point to a substantial public health impact of PCV13 against pneumonia hospitalizations among children < 5 years in Burkina Faso.